Penserra Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Penserra Capital Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-334	Closed	-$8K	–	1255
2022 Q2	$8K	Buy	334 +194	+139%	+$8.63K	﹤0.01%	1314
2022 Q1	$11K	Buy	140 +28	+25%	+$3.46K	﹤0.01%	1398
2021 Q4	$22K	Buy	+112	New	+$27.9K	﹤0.01%	1229
2021 Q3	–	Sell	-166	Closed	-$43K	–	1536
2021 Q2	$43K	Sell	166 -20	-11%	-$6.09K	﹤0.01%	1038
2021 Q1	$71K	Buy	+186	New	+$75K	﹤0.01%	759

Other funds holding VINC

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Penserra Capital Management's VINC Position: Q3 2022 in Review

Penserra Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2022, closing a stake of 334 shares — an estimated $8K sold.

Penserra Capital Management first reported a position in VINC in Q1 2021 and held it in 5 quarters. The position peaked at $71K in Q1 2021. 42 funds tracked by Wall St. Rank hold VINC as of Q3 2022.

Penserra Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 334 Vincerx Pharma, Inc. Common Stock shares in Q3 2022, an estimated $8K.
Penserra Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Penserra Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $71K in Q1 2021.
42 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.